Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCV
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study was to assess in subjects with chronic hepatitis C (treatment-naïve,
genotype 1) receiving weight-based doses of ribavirin the virologic response to 3 dose levels
of Locteron™, dosed every 2 weeks, in comparison with PEG-Intron™ dosed weekly.